Most-Upgraded StocksMost-UpgradedNYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free EW Stock Alerts $85.24 +0.18 (+0.21%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$85.21▼$86.9450-Day Range$84.23▼$95.5652-Week Range$60.57▼$96.12Volume2.33 million shsAverage Volume3.00 million shsMarket Capitalization$51.37 billionP/E Ratio36.74Dividend YieldN/APrice Target$92.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Edwards Lifesciences alerts: Email Address Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.53 Rating ScoreUpside/Downside8.8% Upside$92.71 Price TargetShort InterestHealthy1.25% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.71Based on 33 Articles This WeekInsider TradingSelling Shares$20.92 M Sold Last QuarterProj. Earnings Growth12.27%From $2.77 to $3.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.55 out of 5 starsMedical Sector547th out of 5,430 stocksSurgical Appliances & Supplies Industry31st out of 108 stocks 2.3 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.25% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 28.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.6 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Edwards Lifesciences this week, compared to 11 articles on an average week.Search InterestOnly 7 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 44 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -12% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,920,934.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.27% in the coming year, from $2.77 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 36.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 36.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 259.19.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 3.55. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 7.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesMay 3, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) Director Sells $2,487,999.50 in StockMay 2, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,212,624.00 in StockMay 4, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...May 1, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 7,250 SharesApril 16, 2024 | insidertrades.comThe 5 Stocks Most Sold By Insiders This Year (EW)April 9, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,329,408.00 in StockMay 4, 2024 | americanbankingnews.comMichael A. Mussallem Sells 29,350 Shares of Edwards Lifesciences Co. (NYSE:EW) StockMay 4, 2024 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 4, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...May 3, 2024 | americanbankingnews.comJean-Luc M. Lemercier Sells 14,400 Shares of Edwards Lifesciences Co. (NYSE:EW) StockApril 30, 2024 | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Call TranscriptApril 30, 2024 | markets.businessinsider.comHold Rating Justified for Edwards Lifesciences Amid TAVR Segment UncertaintiesApril 30, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Upgraded by StockNews.com to "Buy"April 29, 2024 | americanbankingnews.comEvercore ISI Cuts Edwards Lifesciences (NYSE:EW) Price Target to $89.00April 29, 2024 | americanbankingnews.comStifel Nicolaus Raises Edwards Lifesciences (NYSE:EW) Price Target to $85.00April 29, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Edwards Lifesciences Co. Raised by Analyst (NYSE:EW)April 28, 2024 | americanbankingnews.comPiper Sandler Increases Edwards Lifesciences (NYSE:EW) Price Target to $88.00April 28, 2024 | americanbankingnews.comWells Fargo & Company Increases Edwards Lifesciences (NYSE:EW) Price Target to $99.00April 27, 2024 | finance.yahoo.comEdwards Lifesciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 27, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)April 27, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Stock Price Down 3.7% After Analyst DowngradeApril 26, 2024 | markets.businessinsider.comStrong Q1 Performance and Positive Market Trends Reinforce Buy Rating for Edwards LifesciencesApril 26, 2024 | finance.yahoo.comEdwards Lifesciences Corp (EW) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...April 26, 2024 | finance.yahoo.comThis 'Critical' Business Helped Edwards Lifesciences Offset Its TAVR MissApril 26, 2024 | benzinga.comDecoding Edwards Lifesciences's Options Activity: What's the Big Picture?April 25, 2024 | investorplace.comEW Stock Earnings: Edwards Lifesciences Beats EPS, Beats Revenue for Q1 2024April 25, 2024 | seekingalpha.comEdwards Lifesciences Non-GAAP EPS of $0.66 beats by $0.02, revenue of $1.6B beats by $30MSee More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/25/2024Today5/04/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$92.71 High Stock Price Target$107.00 Low Stock Price Target$57.00 Potential Upside/Downside+8.8%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$2.32 Trailing P/E Ratio36.74 Forward P/E Ratio30.77 P/E Growth3.58Net Income$1.40 billion Net Margins23.01% Pretax Margin26.19% Return on Equity22.86% Return on Assets16.52% Debt Debt-to-Equity Ratio0.08 Current Ratio3.75 Quick Ratio2.67 Sales & Book Value Annual Sales$6.00 billion Price / Sales8.55 Cash Flow$2.77 per share Price / Cash Flow30.78 Book Value$11.93 per share Price / Book7.15Miscellaneous Outstanding Shares602,600,000Free Float594,826,000Market Cap$51.37 billion OptionableOptionable Beta1.10 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 56)CEO & Director Comp: $2.27MMr. Scott B. Ullem (Age 57)Corporate VP & CFO Comp: $1.35MMr. Donald E. Bobo Jr. (Age 62)Corporate Vice President of Strategy & Corporate Development Comp: $1.27MMr. Larry L. Wood (Age 58)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.49MDr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 65)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMs. Christine Z. McCauley (Age 59)Corporate Vice President of Human Resources Mr. Gary I. Sorsher (Age 59)Senior Vice President of Quality & Regulatory Compliance More ExecutivesKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNDexComNASDAQ:DXCMView All CompetitorsInsiders & Institutions9258 Wealth Management LLCBought 274 shares on 5/4/2024Ownership: 0.002%Team Hewins LLCSold 256 shares on 5/4/2024Ownership: 0.001%Csenge Advisory GroupSold 381 shares on 5/4/2024Ownership: 0.001%Whittier Trust Co.Sold 180 shares on 5/3/2024Ownership: 0.002%Clarity Capital Partners LLCSold 360 shares on 5/3/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: Edwards Lifesciences has shown consistent growth in its stock price, reaching a 52-week high of $95.27. The company's focus on structural heart disease and critical care monitoring products positions it well in the healthcare sector, which has long-term growth potential. Recent institutional investments in the company indicate confidence from major players in the market. Edwards Lifesciences' innovative transcatheter heart valve replacement products under the SAPIEN family offer minimally invasive solutions for aortic valve replacement. The company's strong financial health, with a current ratio of 3.38 and a quick ratio of 2.40, provides stability and liquidity for investors. Cons Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: The company's price-to-earnings ratio of 40.13 and price-to-earnings-growth ratio of 4.61 may indicate a relatively high valuation compared to industry peers. While the company has shown growth, there may be increased competition in the healthcare sector, leading to potential market share challenges. Fluctuations in healthcare regulations and reimbursement policies could impact Edwards Lifesciences' revenue and profitability. Market volatility and macroeconomic factors could affect the company's stock performance, making it susceptible to external economic conditions. Investors should consider the company's debt-to-equity ratio of 0.09 as part of their risk assessment when investing in Edwards Lifesciences. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com. EW Stock Analysis - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EW shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price target for 2024? 17 Wall Street analysts have issued 1-year price targets for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they anticipate the company's stock price to reach $92.71 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2024? Edwards Lifesciences' stock was trading at $76.25 at the start of the year. Since then, EW shares have increased by 11.8% and is now trading at $85.24. View the best growth stocks for 2024 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 7,380,000 shares, a decline of 28.9% from the March 31st total of 10,380,000 shares. Based on an average daily volume of 3,970,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.3% of the company's stock are short sold. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) released its earnings results on Thursday, April, 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The medical research company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a trailing twelve-month return on equity of 22.86%. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Honeytree U.S. Equity ETF (BEEZ), Fundamentals First ETF (KNOW), Guru Favorite Stocks ETF (GFGF), Tema Cardiovascular and Metabolics ETF (HRTS), Global X Aging Population ETF (AGNG), IQ Winslow Focused Large Cap Growth ETF (IWFG) and Fidelity Disruptive Medicine ETF (FMED). When did Edwards Lifesciences' stock split? Edwards Lifesciences's stock split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences issued an update on its second quarter 2024 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of 0.670-0.710 for the period, compared to the consensus estimate of 0.700. The company issued revenue guidance of $1.6 billion-$1.7 billion, compared to the consensus revenue estimate of $1.6 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (3.15%), Nordea Investment Management AB (0.35%), Raymond James & Associates (0.29%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), Raymond James Financial Services Advisors Inc. (0.19%) and Assenagon Asset Management S.A. (0.15%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More This page (NYSE:EW) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.